Genetic factors contributing to late adverse musculoskeletal effects in childhood acute lymphoblastic leukemia survivors

Pharmacogenomics J. 2022 Feb;22(1):19-24. doi: 10.1038/s41397-021-00252-6. Epub 2021 Aug 26.

Abstract

Background: A substantial number of survivors of childhood acute lymphoblastic leukemia (ALL) suffer from treatment-related late adverse effects. While multiple studies have identified the effects of chemotherapeutics and radiation therapy on musculoskeletal outcomes, few have investigated their associations with genetic factors.

Methods: Here we analyzed musculoskeletal complications in relation to common and rare genetic variants derived through whole-exome sequencing of the PETALE cohort. Top-ranking associations were further assessed through stratified and multivariate analyses.

Results: DUOX2 variant was associated with skeletal muscle function deficit, as defined by peak muscle power Z score ≤ -2 SD (P = 4.5 × 10-5 for genotyping model). Upon risk stratification analysis, common variants in the APOL3, COL12A1, and LY75 genes were associated with Z score ≤ -2 SD at the cross-sectional area (CSA) at 4% radial length and lumbar bone mineral density (BMD) in high-risk patients (P ≤ 0.01). The modulation of the effect by risk group was driven by the interaction of the genotype with cumulative glucocorticoid dose. Identified variants remained significant throughout multivariate analyses incorporating non-genetic factors of the studied cohort.

Conclusion: This exploratory study identified novel genetic variants associated with long-term musculoskeletal impairments in childhood ALL survivors. Replication in an independent cohort is needed to confirm the association found in this study.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Anatomy, Cross-Sectional
  • Bone Density
  • Chemoradiotherapy / adverse effects
  • Child
  • Child, Preschool
  • Cohort Studies
  • Dual Oxidases / genetics
  • Exome Sequencing
  • Female
  • Genetic Variation
  • Genotype
  • Humans
  • Infant
  • Lumbar Vertebrae
  • Male
  • Muscle Weakness / etiology
  • Muscle Weakness / genetics
  • Muscle, Skeletal / pathology
  • Musculoskeletal Diseases / etiology*
  • Musculoskeletal Diseases / genetics*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • Risk Assessment
  • Survivors
  • Young Adult

Substances

  • Dual Oxidases
  • DUOX2 protein, human

Grants and funding